Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares Outstanding
Ratios

Burning Rock Biotech (BNR) Non-Current Receivables (2019 - 2024)

Burning Rock Biotech has reported Non-Current Receivables over the past 6 years, most recently at $758000.0 for Q3 2024.

  • For Q3 2024, Non-Current Receivables rose 8.29% year-over-year to $758000.0; the TTM value through Sep 2024 reached $758000.0, up 8.29%, while the annual FY2023 figure was $749000.0, 1.22% up from the prior year.
  • Non-Current Receivables for Q3 2024 was $758000.0 at Burning Rock Biotech, up from $732000.0 in the prior quarter.
  • Over five years, Non-Current Receivables peaked at $758000.0 in Q3 2024 and troughed at $31989.4 in Q4 2020.
  • A 5-year average of $542546.7 and a median of $704000.0 in 2022 define the central range for Non-Current Receivables.
  • Biggest five-year swings in Non-Current Receivables: tumbled 99.7% in 2020 and later surged 625.77% in 2022.
  • Year by year, Non-Current Receivables stood at $31989.4 in 2020, then soared by 368.91% to $150000.0 in 2021, then soared by 378.52% to $717783.8 in 2022, then increased by 2.94% to $738880.9 in 2023, then grew by 2.59% to $758000.0 in 2024.
  • Business Quant data shows Non-Current Receivables for BNR at $758000.0 in Q3 2024, $732000.0 in Q2 2024, and $737000.0 in Q1 2024.